Julius Knowles
Independent DirectorMr. Julius Knowles, also known as Jay, MBA. & Ph.D., serves as a Partner at Mass General Brigham Ventures, LLC. Mr. Knowles serves as the President or Chief Executive Officer of venture and angel-backed companies, as Chief Executive Officer at X-BODY Biosciences from March 2012 to January 2014. Mr. Julius Knowles serves as Director at Tilos Therapeutics, Inc. Mr. Knowles serves as a Director at Paros Bio, Inc. He served as a Director at ROME Therapeutics, Inc. until he left the firm in 2022. He has been Independent Director at Keros Therapeutics, Inc. since April 2016. He also serves as the Director of Abcuro, Inc. He served as Director until 2023 and serves as Board observer since 2023 at SwanBio Therapeutics Ltd. He is a Co-Founder of Novalar Pharmaceuticals and served as its President, where he led the development of a first-in-class local anaesthesia release agent. He was also the Executive Vice President of Business Development at Novalar Pharmaceuticals, Inc. Since January 2014, Mr. Knowles has served as a Partner at Mass General Brigham Ventures (formerly known as PartnersInnovation Fund. He was responsible for business strategy and forging of strategic alliances. He served as Head of Strategic Alliances for Platform Technologies and Director of Strategic Alliances of Novartis Pharmaceuticals, where he led a team responsible for creating technology-based and drug discovery collaborations, forging a number of major strategic alliances with biotech companies. Mr. Knowles served as Vice President of Business Development for SGX Pharmaceuticals, Inc. He served as Principal at BioVentures Investors LLC. He was also the Vice President of Business Development at Novacea. Mr. Knowles served as Vice President of Business Development at Structural GenomiX Inc. He was responsible for its business strategy and forging of strategic alliances. Mr. Knowles worked at Vertex Pharmaceuticals Incorporated for some years in various roles and served as Director of Research and Development Planning from 1993 to 1999. During his tenure, Vertex grew from 60 to 350 people, launched a drug and put ten compounds into the clinic, mainly due to the strength of Vertex's structural solutions. At Vertex, he closed a wide variety of corporate collaborations with pharma, biotech and academia. Mr. Knowles served as a Member of the Board of Directors of Abcuro, Inc. and serves as its Board Observer and serves as a Director of Tilos Therapeutics, Inc. He was Director at Aurigene Discovery Technologies Limited until he left the firm in September 2019. He is Director at X-BODY. He represents the fund as a Board Observer at RaNA Therapeutics. He is a Director of Apres Therapeutics and Triplet Therapeutics. He is an experienced business development professional with many years in the industry and has guided multiple early-stage companies through drug discovery and development. Prior to Wharton, he worked in marketing for Hewlett-Packard. Mr. Knowles received his MBA in Finance from The Wharton School at the University of Pennsylvania. Mr. Knowles received M.Sc. in Chemistry from University of California, Berkeley and a BA with Distinction in Chemistry from Carleton College.
Positions
- Company NameKeros Therapeutics, Inc.Stock CodeKROSPositionIndependent DirectorColleagues
- JSJasbir S. SeehraPresident, CEO & Director
- JBJean-Jacques BienaimeIndependent Chair of the Board
- ECEsther ChoChief Legal Officer & Secretary
- ATAnnita TaniniVP of Finance, Corporate Controller and Interim Principal Financial & Accounting Officer
- JFJustin FrantzHead of Investor Relations
- LLLorena LernerChief Scientific Officer
- MAMary Ann GrayIndependent Director
- AHAlpna Hansraj SethIndependent Director
